Cornerstones Best of DDW in IBD Podium to Practice 2018

Cornerstones Best of DDW in IBD Podium to Practice 2018

On-Demand Webcast
Course Directors

Marla Dubinsky, MD
Icahn School of Medicine, Mount Sinai Medical Center, NY

David Rubin, MD
The University of Chicago Medicine, IL


David Binion, MD
University of Pittsburgh, PA

Susan Connor, MBBS, PhD, FRACP
Liverpool Hospital, Sydney, Australia

Richard Gearry, MBChB, FRACP, PhD
University of Otago, Christchurch, NZ

Peter Irving, MA, MD, FRCP
Guy’s & St. Thomas’ Hospital, London, UK

Asher Kornbluth, MD
Mount Sinai Medical Center, NY

James Lindsay, FRCP, PhD
Barts Health, London, UK

Edward Loftus, MD
Mayo Clinic – Rochester, MN

Uma Mahadevan, MD
University of California, San Francisco, CA

Dermot McGovern, MD, PhD, FRCP
Cedars-Sinai Medical Center, CA

David Ong, MBChB, FRCP, FAMS
National University Hospital, Singapore

Miguel Regueiro, MD
Cleveland Clinic, OH

Corey Seigel, MD
Dartmouth-Hitchcock Medical Center, NH

Miles Sparrow, MBBS, FRCP
The Alfred Hospital, Melbourne, Australia

Thomas Ullman, MD
Montefiore Health System, NY

Target Audience

This educational activity is specifically designed for gastroenterologists, hospitalists, internal medicine specialists, and other healthcare professionals (physicians-in-training, nurses, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with IBD.


Cornerstones presents our Best of DDW in IBD Podium to Practice Webseries programs. In these exclusive webisodes, our expert international faculty extract the most up-to-date insights and developments from DDW, bringing cutting-edge information straight from the podium to turn it into practical and actionable knowledge to benefit your practice.


Upon successful completion of this educational activity, participants should be better able to:

  1. Incorporate advances in therapeutic options and understanding of biologics and small molecules for the treatment of Crohn’s disease and ulcerative colitis
  2. Incorporate advances in therapeutic options and understanding of non-biologic and non-medical therapies for the treatment of both Crohn’s disease and ulcerative colitis
  3. Consider the implications for short-term outcomes in IBD based on clinical presentation and treatment strategy
  4. Incorporate quality measures to improve patient health or quality-of-life outcomes

Release Date: July 10, 2018

Expiration Date: July 10, 2019


This activity is provided by Imedex®, LLC.

Continuing Education


Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this internet-based enduring educational activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.5 hour of Category 1 credit for completing this program.

In order to receive credit, participants must successfully complete the post-test and complete the online evaluation form. You will receive an online CME statement of credit to print for your records.


Supported by educational grants from: AbbVie, Celgene, Merck Sharp & Dohme, Pfizer, Prometheus, Salix Pharmaceuticals, and Takeda Pharmaceuticals


As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), Imedex, LLC must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are instructed to provide a balanced view of therapeutic options by utilizing generic names to ensure impartiality.

All faculty participating in an Imedex activity are required to disclose relevant financial relationships that may be considered to be related to the subject matter of the educational activity. Disclosure of these commitments and/or relationships is included in these course materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

The following indicates the faculty disclosure declaration information and the nature of those commercial relationships.

1=grant/research support 2=consultant 3=speaker’s bureau 4=stock shareholder 5=other support

David Binion, MD AbbVie1,2; Merck2; Shire2; Takeda Pharmaceuticals2
Susan Connor, MBBS, PhD, FRACP AbbVie1,2,3; Celgene1; Ferring1,2,3; Janssen1,2,3; Merck Sharp & Dohme1,2; Pfizer1,2,3; Ramsey Healthcare5; Shire2,3; Sonic Pathology5; Takeda Pharmaceuticals1,2,3; Vectos Biosystems5
Marla Dubinsky, MD AbbVie1; Boehringer Ingelheim1; Celgene1; Cornerstones Health4; Genentech1; Janssen1; Pfizer1; Prometheus Labs1; Salix Pharmaceuticals1; Takeda Pharmaceuticals1; UCB1
Richard Gearry, MBChB, FRACP, PhD AbbVie1,2; Zespri International1,2
Peter Irving, MA, MD, FRCP AbbVie1,3; Falk3; Ferring3; Janssen1,2,3; Lilly3; Merck Sharp & Dohme1,2,3; Pfizer1,3; Samsung Bioepis3; Shire3; Takeda Pharmaceuticals1,2,3; Tilott’s3; Topivert3; VH2,3; Warner Chilcott3
Asher Kornbluth, MD AbbVie1,2,3; Boehringer Ingelheim1; Janssen1,2,3; Merck1,2,3; Pfizer1,2; Prometheus Labs1,2; Takeda Pharmaceuticals1,2,3
James Lindsay, FRCP, PhD AbbVie1,3; Allergan1,3; Atlantic Healthcare1; Celgene1,3; Celltrion1,3; Ferring1,3; GlaxoSmithKline1; Janssen1,3; Merck Sharp & Dohme1,3; Napp1,3; Pfizer1,2,3; Shire1,2,3; Takeda Pharmaceuticals1,2,3
Edward Loftus, MD AbbVie1,2; Amgen1,2; Celgene1,2; Celltrion Healthcare1; Eli Lilly1; Genentech2; Gilead2; Janssen1,2; MedImmune2; Napo Pharmaceuticals1; Pfizer1,2; Robarts Clinical Trials2; Seres2; Takeda Pharmaceuticals1,2; UCB1,2
Uma Mahadevan, MD AbbVie1; Celgene1; Janssen1; Pfizer1,2; Takeda Pharmaceuticals1,2
Dermot McGovern, MD, PhD, FRCP Genentech1; Gilead1; Janssen2; Pfizer1; Precision IBD1
David Ong, MBChB, FRCP, FAMS AbbVie1,3; Ferring1,2,3; Janssen1,3; Shire1,3; Takeda Pharmaceuticals1,3; Vifor1,2,3
Miguel Regueiro, MD AbbVie1,2; Allergan1; Amgen1; Celgene1; Janssen1,2; Miraca Labs1; Pfizer1,2; Salix Pharmaceuticals2; Seres1; Shire2; Takeda Pharmaceuticals1,2; UCB1,2
David Rubin, MD AbbVie1,2; Abgenomics1; Allergan1; Amgen1; Celgene1; Cornerstones Health4; Forward Pharma1; Genentech1,2; Janssen1,2; Merck1; Miraca Life Sciences1; Mitsubishi Tanabe Pharma Dev Amer1; Napo Pharmaceuticals1; Pfizer1; Prometheus Labs2; Salix Pharmaceuticals1; Samsung Bioepis1; Sandoz1; Shire1,2; Takeda Pharmaceuticals1,2; Target PharmaSolutions1; UCB2
Corey Seigel, MD AbbVie1,2; AHRQ2; Amgen1; Broad Medical Research2; CCFA2; Celgene1; Eli Lily1; Janssen1,2; Pfizer1,2; Prometheus Labs1; Sandoz1; Sebela1; Takeda Pharmaceuticals1,2
Miles Sparrow, MBBS, FRCP AbbVie1; Celgene1; Ferring3; Janssen1; Pfizer1; Merck Sharp & Dohme1; Takeda Pharmaceuticals1
Thomas Ullman, MD Janssen1; Pfizer1; Salix Pharmaceuticals1

All materials are included with the permission of the authors.

Imedex, LLC Staff Disclosure of Financial Relationships
All Imedex staff members who are in a position to control content of this activity have no financial relationships with any commercial interests, except for the following individuals:

   Chris Bolwell owns shares of stock of GlaxoSmithKline.

Unapproved Uses

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.

The opinions expressed in this webcast are the opinions of the authors and do not necessarily reflect the opinions of Imedex.


The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

About Imedex

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

© 2018 Imedex, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.

For comments or inquiries, please contact:
Imedex, LLC
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Fax: +1(770) 751-7334